Beam Therapeutics (NASDAQ:BEAM) Earns Overweight Rating from Cantor Fitzgerald
Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. BEAM has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price objective on shares of Beam Therapeutics in a […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “overweight” rating reaffirmed by research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. BEAM has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price objective on shares of Beam Therapeutics in a […]
